FibroBiologics Inc (FBLG) USD0.00001
Sell:$0.94Buy:$0.97
$0.06
(5.82%)
- This stock can be held in a
Stocks and Shares ISA$0.06
(5.82%)$0.06
(5.82%)Company Information
About this company
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Key people
Key facts
- EPICFBLG
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS31573L1052
- Market cap$38.65m
- Employees13
- Shares in issue38.26m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.